Patents by Inventor Jinlin Hou

Jinlin Hou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISDIAZABICYCLO COMPOUND FOR TREATING AND/OR PREVENTING HEPATITIS VIRUS-RELATED DISEASES OR DISORDERS
    Publication number: 20220296571
    Abstract: Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders.
    Type: Application
    Filed: April 8, 2022
    Publication date: September 22, 2022
    Inventors: Yifan Zhai, Xiaoyong Zhang, Jinlin Hou, Dajun Yang
  • Bisdiazabicyclo compound for treatment and/or prevention of hepatitis virus-related diseases or disorders
    Patent number: 11298339
    Abstract: Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: April 12, 2022
    Assignees: JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC., HEALTHQUEST PHARMA INC.
    Inventors: Yifan Zhai, Xiaoyong Zhang, Jinlin Hou, Dajun Yang
  • TREATMENT METHOD WITH IAP INHIBITOR
    Publication number: 20220047606
    Abstract: Improved methods for treating hepatitis B (HB) in patients with (5S,5?S,8S,8?S,10aR,10a?R)-3,3?-(1,3-phenylenedisulfonyl)bis(N-benzhydryl-5-((S)-2-(methylamino)propanamido)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide) (Compound (I)) are disclosed herein. Dosing regimens of Compound (I) for the treatment of HBV infection are provided.
    Type: Application
    Filed: November 19, 2020
    Publication date: February 17, 2022
    Inventors: Yifan Zhai, Xiaoyong Zhang, Jinlin Hou, Dajun Yang
  • BISDIAZABICYCLO COMPOUND FOR TREATMENT AND/OR PREVENTION OF HEPATITIS VIRUS-RELATED DISEASES OR DISORDERS
    Publication number: 20210290594
    Abstract: Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders.
    Type: Application
    Filed: November 20, 2018
    Publication date: September 23, 2021
    Inventors: Yifan Zhai, Xiaoyong Zhang, Jinlin Hou, Dajun Yang
  • Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof
    Patent number: 7320857
    Abstract: Severe Acute Respiratory Syndrome (“SARS”) is a human respiratory disease of recent origin, widespread infectivity, recurring incidence, and significant mortality. Although there is abundant evidence suggesting that the coronavirus responsible for the disease (“SARS-CoV”) evolves during an outbreak, there is currently little data on the earliest strains of this coronavirus. The present invention is directed to the characterization of the genomic RNA sequences of these earliest SARS coronaviruses, to the identification of nucleotide positions within the SARS-CoV genomic RNA that are characteristic of the different evolutionary stages of the coronavirus, to kits based on these positions for use in diagnosis of the disease in patients, and for the development of vaccines to the disease based on the lowered virulence and contagiousness of these earliest strains of SARS-CoV.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: January 22, 2008
    Assignee: Chinese National Human Genome Center at Shanghai
    Inventors: Guoping Zhao, Rui Heng Xu, Xinwei Wu, Changchun Tu, Huai-Dong Song, Yixue Li, Jinlin Hou, Jun Xu, Jun Min
  • Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof
    Publication number: 20050112554
    Abstract: Severe Acute Respiratory Syndrome (“SARS”) is a human respiratory disease of recent origin, widespread infectivity, recurring incidence, and significant mortality. Although there is abundant evidence suggesting that the coronavirus responsible for the disease (“SARS-CoV”) evolves during an outbreak, there is currently little data on the earliest strains of this coronavirus. The present invention is directed to the characterization of the genomic RNA sequences of these earliest SARS coronaviruses, to the identification of nucleotide positions within the SARS-CoV genomic RNA that are characteristic of the different evolutionary stages of the coronavirus, to kits based on these positions for use in diagnosis of the disease in patients, and for the development of vaccines to the disease based on the lowered virulence and contagiousness of these earliest strains of SARS-CoV.
    Type: Application
    Filed: July 9, 2004
    Publication date: May 26, 2005
    Inventors: Guoping Zhao, Rui Heng Xu, Xinwei Wu, Changchun Tu, Huai-Dong Song, Yixue Li, Jinlin Hou, Jun Xu, Jun Min